Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies
- PMID: 23637108
- PMCID: PMC3640214
- DOI: 10.1192/bjp.bp.112.118307
Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies
Abstract
Background: Late-life depression may increase the risk of incident dementia, in particular of Alzheimer's disease and vascular dementia.
Aims: To conduct a systematic review and meta-analysis to evaluate the risk of incident all-cause dementia, Alzheimer's disease and vascular dementia in individuals with late-life depression in population-based prospective studies.
Method: A total of 23 studies were included in the meta-analysis. We used the generic inverse variance method with a random-effects model to calculate the pooled risk of dementia, Alzheimer's disease and vascular dementia in older adults with late-life depression.
Results: Late-life depression was associated with a significant risk of all-cause dementia (1.85, 95% CI 1.67-2.04, P<0.001), Alzheimer's disease (1.65, 95% CI 1.42-1.92, P<0.001) and vascular dementia (2.52, 95% CI 1.77-3.59, P<0.001). Subgroup analysis, based on five studies, showed that the risk of vascular dementia was significantly higher than for Alzheimer's disease (P = 0.03).
Conclusions: Late-life depression is associated with an increased risk for all-cause dementia, vascular dementia and Alzheimer's disease. The present results suggest that it will be valuable to design clinical trials to investigate the effect of late-life depression prevention on risk of dementia, in particular vascular dementia and Alzheimer's disease.
Conflict of interest statement
In the past 3 years B.S.D. has received payment for lectures from Novartis and had travel/meeting expenses covered by Pfizer. M.A.B. received remuneration for neuropsychological assessment services on a fee-for-service basis, for clinical trials conducted by Northstar Neuroscience and Medtronic and from Fox Learning Systems for developing computerised neuropsychological tasks for an NIH-funded study. The following pharmaceutical companies provide pharmaceutical supplies for C.F.R.’s NIH-sponsored work: Bristol-Myers Squibb, Forrest Laboratories, Lilly and Pfizer.
Figures




Similar articles
-
Nimodipine for primary degenerative, mixed and vascular dementia.Cochrane Database Syst Rev. 2001;(1):CD000147. doi: 10.1002/14651858.CD000147. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2002;(3):CD000147. doi: 10.1002/14651858.CD000147. PMID: 11279679 Updated.
-
Selegiline for Alzheimer's disease.Cochrane Database Syst Rev. 2003;(1):CD000442. doi: 10.1002/14651858.CD000442. Cochrane Database Syst Rev. 2003. PMID: 12535396
-
¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).Cochrane Database Syst Rev. 2015 Jan 28;1(1):CD010632. doi: 10.1002/14651858.CD010632.pub2. Cochrane Database Syst Rev. 2015. PMID: 25629415 Free PMC article.
-
Nimodipine for primary degenerative, mixed and vascular dementia.Cochrane Database Syst Rev. 2000;2002(2):CD000147. doi: 10.1002/14651858.CD000147. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2001;(1):CD000147. doi: 10.1002/14651858.CD000147. PMID: 10796495 Free PMC article. Updated.
-
Nimodipine for primary degenerative, mixed and vascular dementia.Cochrane Database Syst Rev. 2002;(3):CD000147. doi: 10.1002/14651858.CD000147. Cochrane Database Syst Rev. 2002. PMID: 12137606
Cited by
-
Socioeconomic and psychosocial mechanisms underlying racial/ethnic disparities in cognition among older adults.Neuropsychology. 2021 Mar;35(3):265-275. doi: 10.1037/neu0000720. Neuropsychology. 2021. PMID: 33970660 Free PMC article.
-
The double burden of age and major depressive disorder on the cognitive control network.Psychol Aging. 2015 Jun;30(2):475-85. doi: 10.1037/pag0000027. Psychol Aging. 2015. PMID: 26030776 Free PMC article.
-
Factors predicting episodic memory changes in older adults with subjective cognitive decline: A longitudinal observational study.Geriatr Nurs. 2021 Jan-Feb;42(1):268-275. doi: 10.1016/j.gerinurse.2020.08.016. Epub 2020 Sep 9. Geriatr Nurs. 2021. PMID: 32919799 Free PMC article.
-
Therapeutic Opportunities for Food Supplements in Neurodegenerative Disease and Depression.Front Nutr. 2021 May 14;8:669846. doi: 10.3389/fnut.2021.669846. eCollection 2021. Front Nutr. 2021. PMID: 34055858 Free PMC article. Review.
-
Exploring Language Learning as a Potential Tool against Cognitive Impairment in Late-Life Depression: Two Meta-Analyses and Suggestions for Future Research.Behav Sci (Basel). 2020 Aug 31;10(9):132. doi: 10.3390/bs10090132. Behav Sci (Basel). 2020. PMID: 32878051 Free PMC article. Review.
References
-
- Butters MA, Becker JT, Nebes RD, Zmuda MD, Mulsant BH, Pollock BG, et al. Changes in cognitive functioning following treatment of late-life depression. Am J Psychiatry 2000; 157: 1949–54 - PubMed
-
- Lenoir H, Dufouil C, Auriacombe S, Lacombe JM, Dartigues JF, Ritchie K, et al. Depression history, depressive symptoms, and incident dementia: the 3C Study. J Alzheimers Dis 2011; 26: 27–38 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical